Cardlytics, Inc (CDLX) Income Statement
CDLX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCDLX revenue and net income
Where CDLX's revenue goes
2025Each bar shows an amount and its share of revenue. CDLX kept −44.4% of revenue as net income.
CDLX profit margins
CDLX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −16.2% | −7.9% | +4.5% | +11.6% |
| Gross profit | −13.1% | −2.3% | +10.7% | +15.4% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CDLX quarterly EPS vs estimates
Cardlytics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 4, 2026 (estimate $-1.04).
CDLX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $233.3M | $278.3M | $309.2M | $298.5M | $267.1M | $186.9M | $210.4M | $150.7M | $130.4M | $112.8M |
| Cost of revenue | $128.2M | $157.4M | $178.8M | $185.9M | $163.8M | $123.6M | $131.0M | $96.0M | $80.3M | $72.4M |
| Gross profit | $105.1M | $120.9M | $130.4M | $112.6M | $103.3M | $63.3M | $79.5M | $54.7M | $50.1M | $40.4M |
| Research & development | $39.8M | $49.6M | $51.4M | $54.4M | $38.1M | $17.5M | $11.7M | $16.2M | $12.2M | $13.9M |
| Sales, general & admin | $86.7M | $109.1M | $116.2M | $156.2M | $132.2M | $91.8M | $80.5M | $76.1M | $52.0M | $52.6M |
| Total operating expenses | $152.2M | $316.4M | $266.0M | $570.4M | $225.9M | $117.2M | $96.8M | $95.6M | $67.2M | $70.7M |
| Operating income | −$47.1M | −$195.5M | −$135.7M | −$457.8M | −$122.6M | −$53.9M | −$17.3M | −$40.9M | −$17.1M | −$56.2M |
| Interest income | $2.7M | $3.4M | $3.8M | $1.4M | $297,000 | $733,000 | $829,000 | $11.2M | $2.5M | $17.1M |
| Interest expense | $10.6M | $8.9M | $6.2M | $4.0M | $12.9M | $3.5M | $1.4M | $3.3M | $8.2M | $6.2M |
| Income before taxes | −$103.5M | −$189.3M | −$134.7M | −$466.7M | −$136.4M | −$55.4M | −$17.1M | −$53.0M | −$19.6M | −$75.7M |
| Income taxes | — | — | $134.7M | −$1.4M | −$7.9M | $3.0M | $548,000 | −$12.1M | $5.7M | $32.1M |
| Net income | −$103.5M | −$189.3M | −$134.7M | −$465.3M | −$128.6M | −$55.4M | −$17.1M | −$53.0M | −$19.6M | −$75.7M |
| EBITDA | −$65.4M | −$152.5M | −$99.0M | −$420.4M | −$88.2M | −$40.8M | −$12.1M | −$46.0M | −$8.4M | −$24.0M |
| EPS (diluted) | −$4.73 | −$4.21 | −$4.66 | −$15.61 | −$10.75 | −$8.03 | −$3.02 | −$7.16 | −$1.41 | −$53.96 |
| Gross margin | 45.0% | 43.4% | 42.2% | 37.7% | 38.7% | 33.9% | 37.8% | 36.3% | 38.4% | 35.8% |
| Operating margin | −20.2% | −70.2% | −43.9% | −153.3% | −45.9% | −28.9% | −8.2% | −27.2% | −13.1% | −49.8% |
| Net margin | −44.4% | −68.0% | −43.6% | −155.8% | −48.1% | −29.7% | −8.1% | −35.2% | −15.1% | −67.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.9M | $34.3M | $56.1M | $52.0M | $63.2M | $61.9M | $74.0M | $67.1M | $69.6M | $67.6M | $89.2M | $79.0M |
| Cost of revenue | $18.3M | $17.2M | $30.2M | $27.7M | $34.0M | $36.7M | $41.3M | $38.5M | $40.9M | $36.7M | $49.7M | $43.2M |
| Gross profit | $18.6M | $17.1M | $25.9M | $24.3M | $29.3M | $25.2M | $32.7M | $28.6M | $28.7M | $30.9M | $39.5M | $35.8M |
| Research & development | $5.5M | $6.4M | $8.0M | $8.8M | $11.3M | $11.7M | $9.9M | $13.2M | $13.5M | $13.0M | $12.5M | $12.4M |
| Sales, general & admin | $14.5M | $15.0M | $15.8M | $18.7M | $24.2M | $26.5M | $25.1M | $25.2M | $30.2M | $28.6M | $28.0M | $29.7M |
| Total operating expenses | $24.1M | $25.4M | $30.0M | $93.2M | $42.1M | $39.2M | $41.0M | $177.1M | $44.5M | $53.7M | $142.4M | $56.5M |
| Operating income | −$5.4M | −$8.3M | −$4.1M | −$68.9M | −$12.8M | −$14.1M | −$8.3M | −$148.5M | −$15.8M | −$22.8M | −$102.9M | −$20.7M |
| Interest income | $183,000 | $263,000 | $831,000 | $908,000 | $426,000 | $546,000 | $677,000 | $877,000 | $872,000 | $816,000 | $869,000 | $816,000 |
| Interest expense | $2.3M | $2.8M | $3.0M | $2.9M | $2.4M | $2.4M | $2.4M | $2.4M | $2.4M | $1.7M | $1.7M | $1.7M |
| Income before taxes | −$8.7M | −$13.8M | −$8.2M | −$72.7M | −$9.3M | −$13.3M | −$15.6M | −$145.2M | −$4.3M | −$24.3M | −$100.8M | −$24.0M |
| Income taxes | — | −$9.3M | — | — | — | — | $1,000 | $145.2M | $4.3M | $6.8M | $100.8M | $1.7M |
| Net income | −$14.9M | −$4.5M | −$8.2M | −$72.7M | −$9.3M | −$13.3M | −$15.6M | −$145.2M | −$4.3M | −$24.3M | −$100.8M | −$24.0M |
| EBITDA | −$2.0M | −$6.3M | $1.3M | −$62.8M | $3,000 | −$4.0M | −$6.7M | −$135.3M | $5.2M | −$15.7M | −$92.2M | −$15.6M |
| EPS (diluted) | −$1.50 | −$1.10 | $0.03 | −$1.36 | −$1.30 | −$2.10 | −$0.31 | −$1.50 | −$1.50 | −$0.90 | $0.14 | $0.10 |
| Gross margin | 50.5% | 49.9% | 46.2% | 46.7% | 46.3% | 40.6% | 44.2% | 42.6% | 41.2% | 45.7% | 44.3% | 45.4% |
| Operating margin | −14.8% | −24.1% | −7.3% | −132.3% | −20.2% | −22.7% | −11.2% | −221.5% | −22.7% | −33.8% | −115.4% | −26.1% |
| Net margin | −40.3% | −13.1% | −14.7% | −139.7% | −14.7% | −21.5% | −21.1% | −216.5% | −6.1% | −35.9% | −113.1% | −30.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CDLX's financial statements (latest annual report filed March 4, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CDLX financial results
In fiscal year 2025 (ended December 31, 2025), Cardlytics reported revenue of $233.3 million, down 16.2% from the year before. It had a net loss of $103.5 million, a net profit margin of −44.4%. Diluted earnings per share came to −$4.73. Over five years revenue grew at an average rate of 4.5% a year.
See the CDLX stock overview for the latest quote and news, or the CDLX chart for price history and technical indicators.
CDLX income statement FAQ
What is Cardlytics's annual revenue?
Cardlytics reported total revenue of $233.3 million for fiscal year 2025, which ended on December 31, 2025. That was down 16.2% from $278.3 million the previous year.
Is Cardlytics profitable?
No. Cardlytics reported a net loss of $103.5 million in fiscal 2025, a net profit margin of −44.4%; its operating margin was −20.2%.
What is Cardlytics's gross margin?
Cardlytics's gross margin was 45.0% in fiscal 2025: for every $100 of revenue, Cardlytics kept $45 after the direct cost of its products and services.
How much does Cardlytics spend on research and development?
Cardlytics spent $39.8 million on research and development in fiscal 2025, 17.0% of revenue.
How fast is Cardlytics growing?
Revenue grew 4.5% a year on average over the last five fiscal years, from $186.9 million to $233.3 million.
What are Cardlytics's earnings per share?
Cardlytics earned $-4.73 per diluted share in fiscal 2025, compared with $-4.21 a year earlier.
When will Cardlytics report its next earnings?
Cardlytics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Cardlytics's fiscal year end?
Cardlytics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 4, 2026.